Willingness to Pay

Understanding Willingness to Pay

Medialis can help you to understand and support the needs of all stakeholders who will influence the purchase decision. It is crucial to develop a solid understanding of stakeholders’ perceptions, including consideration of patients and the healthcare professionals who will influence them.

Medialis captures key insights into payor willingness to pay and provides an evidence-based approach to price setting for novel products in multi-payor markets.

Pharmaceutical research is an important engine of innovation and essential to improving the quality and effectiveness of healthcare and the final part of the process includes the successful market access of those medicines

The fragmented nature of European research systems is hindering Europe’s ability to compete with the USA in terms of generating, organising and sustaining innovative processes. This not only hinders the EU research effort but is also leading to a loss of our highly skilled scientists.

In recent years, the United States has been more successful in co-ordinating public and private research. Part of the reason for its success has been the impact of the National Institutes of Health (NIH). Through NIH, the United States Government has been able to bring together scientific knowledge and centers of excellence to meet key public health issues while providing public funding.

The key barrier, identified by the G10 Medicines Group, to making Europe a more dynamic center of research and innovation was the lack of widespread scientific collaboration across national borders and between public and privately funded research. It proposed tackling this issue by establishing European virtual institutes of health combined with greater support for clinical trials and facilitating the development of pediatric and orphan medicines.

Another critical area is biotechnology which is playing an ever greater role in pharmaceuticals. Around one-fifth of new molecular entities launched on the world market are derived from biotechnology [18] and over 50% of those under development are biotech-derived. It is welcome, therefore, that G10 Medicines gave strong support to the Commission Communication on Life Sciences and Biotechnology.

Adapted from the G10 commission meeting 2001

We use cookies to give you the best possible experience. By using our website, you're agreeing to our use of cookies. To find out more read our cookie policy